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esponsibility of InsAbstract A novel class of thioﬂavone and ﬂavonoid derivatives has been prepared and their
antiviral activities against enterovirus 71 (EV71) and the coxsackievirus B3 (CVB3) and B6 (CVB6)
were evaluated. Compounds 7d and 9b showed potent antiviral activities against EV71 with IC50
values of 8.27 and 5.48 mM, respectively. Compound 7f, which has been synthesized for the ﬁrst
time in this work, showed the highest level of inhibitory activity against both CVB3 and CVB6 with
an IC50 value of 0.62 and 0.87 mM. Compounds 4b, 7a, 9c and 9e also showed strong inhibitory
activities against both the CVB3 and CVB6 at low concentrations (IC50¼1.427.15 mM), whereas
compounds 4d, 7c, 7e and 7g showed strong activity against CVB6 (IC50¼2.91–3.77 mM) together
with low levels of activity against CVB3. Compound 7d exhibited stronger inhibitory activity
against CVB3 (IC50¼6.44 mM) than CVB6 (IC5048.29 mM). The thioﬂavone derivatives 7a, 7c, 7d,
7e, 7f and 7g, represent a new class of lead compounds for the development of novel antiviral
agents.
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Dajun Zhang et al.5761. Introduction
The prevention and treatment of viral infectious diseases has
become a global public health problem. The emergence of
drug-resistant and unknown viral infections has made the
development of new antiviral agents with new mechanisms of
action and broad-spectrum levels of activity even more
important. Notably, the number of enterovirus 71 (EV71)
outbreaks in the Asia-Paciﬁc region has increased signiﬁcantly
in recent years, and group B coxsackieviruses (CVB) are
known to be associated with a variety of the acute and chronic
forms of several different diseases.
Human enteroviruses are small, single-stranded, positive-
sense RNA viruses which belongs to the enteroviruses genus of
the picornaviridae family. Like other types of enteroviral
infections, EV71 infections may be asymptomatic or may
cause diarrhea, rashes, vesicular lesions on the hands, feet, and
oral mucosa (hand–foot-and-mouth disease), herpangina,
aseptic meningitis, encephalitis, myocarditis, or a combination
of these conditions. EV71 infections in children have recently
become a signiﬁcant public health problem in China1,2. CVBs
are known to be associated with a variety of acute and chronic
forms of several different diseases, including myocarditis,
meningitis and pancreatitis, especially in neonates, young
children and immune-compromised adult patients. Cardiac
infection with CVB3 can result in acute myocarditis that
spontaneously resolves or chronic myocarditis with prolonged
viral persistence3.
Flavonoids are a group of low molecular weight phenyl
benzopyrones that possess a variety of different pharmacolo-
gical properties, including antioxidant, anticancer, antiviral
and anti-inﬂammatory activities4–6. Some naturally occurring
and modiﬁed ﬂavonoid compounds have been reported to
exhibit a broad spectrum of antiviral activity against picorna-
virus7,8. These compounds were reported to interfere with
picornavirus replication by preventing the decapsidation
of the viral particles and RNA release within the cells.
3-Hydroxyﬂavone was reported to exhibit antiviral activity
against human rhinovirus (HRV)-1B and HRV-14, with IC50
values of 1.3 and 2.1 mM, respectively. Although the molecular
mechanism of action for ﬂavonoids remains unclear, it has
been attributed to interference with the early stages of viral
infection, probably represented by viral RNA synthesis.
Thioﬂavone derivatives are the thio analogues of the
ﬂavonoid derivatives, and some thioﬂavone compounds have
been reported to exhibit antimicrobial activities9. For example,
compounds A and B (Fig. 1) have been reported to exhibit
inhibitory activities against Trichophyton rubrum IFO5467,
with MIC values of 0.19 and 0.05 mg/mL, respectively.Figure 1 Structures of several known ﬂavone and thioﬂavone
analogues.However, there have been no reports concerning their antiviral
activities.
There are currently no effective antiviral drugs in the clinic
for the treatment of EV17 and CVB infections. Treatments for
acute EV71 infections with neurological manifestations are
principally intended to alleviate the symptoms. With this in
mind, herein we describe the synthesis of a series of thio-
ﬂavone analogues and the subsequent in vitro evaluation of
their activities against EV71, CVB3 and CVB6. According to
the principle of bioisosterism, we synthesized a series of
compounds (7a–i) in which the oxygen atom at position 1 of
the ﬂavonoids was replaced with a sulfur atom. To investigate
the effects of methoxyl and hydroxyl groups on the activity of
these compounds, we obtained compounds 8a–c via demethy-
lation of the methoxyl group of 7a–c. Furthermore, several
ﬂavonol derivatives were also synthesized in an attempt to
improve their antiviral potency and to systemically investigate
their antiviral structure activity relationships.2. Results and discussion
2.1. Chemistry
With the exception of compounds 9a–h, which were purchased
from J&K Scientiﬁc, all of the target compounds described in
this paper were synthesized according to well-established
literature procedures10–12. The synthetic schemes are discribed
below (Schemes 1 and 2).
As shown in Scheme 1, compounds 4a–d were successfully
synthesized via the condensation reaction of 2-hydroxy acet-
ophenone (1) with a variety of substituted benzaldehydes (2) in
a mixture of MeOH and KOH. The resulting intermediate
compounds 3a–d were then reacted with hydrogen peroxide
(H2O2) in a mixture of MeOH and KOH at 0–5 1C to provide
the target compounds 4a–d.
4-Methoxybenzenethiol (5) was used as the starting material
for the synthesis of the thiochromen-4-one derivatives (7 and
8). Compound 5 was condensed with the appropriately
substituted ethyl 3-oxopropionates (6) in polyphosphoric acid
to afford compounds 7a–i, according to a published proce-
dure10. These compounds were then treated with boron
tribromide in dichloromethane to affect the ether cleavage to
generate the substituted thioﬂavones 8a–c.
2.2. Biological results and discussion
The antiviral activities of the ﬂavonoids against EV71 (SZ-98),
CVB3 and CVB6 were evaluated using African green monkey
kidney cells (Vero cell) as the virus host. The results are
summarized in Table 1.
As shown in Table 1, compounds 7d and 9b clearly
exhibited the highest levels of inhibitory activity of all of the
compounds tested against EV71, with IC50 values of 8.27 and
5.48 mM, respectively. Unfortunately, they were not as potent
as the reference drug pirodavir, which gave an IC50 of
0.32 mM. Compounds 4b and 7i showed moderate inhibitory
activity against EV71 with IC50 values of 16.90 and 39.63 mM,
respectively, whereas the remaining compounds showed little
to no activity against EV71 under the conditions tested.
The tested compounds showed strong levels of activity
against coxsackieviruses. Compound 4a, for example, showed
Scheme 1 Synthetic route to the ﬂavonoid compounds 4a–d: (a) KOH, CH3OH; (b) KOH, CH3OH, 30% H2O2.
Scheme 2 Synthetic route to the thioﬂavone compounds 8a–c: (a) polyphosphoric acid, 90–100 1C; (b) BBr3, CH2Cl2, r.t.
Table 1 Antiviral activities of the tested compounds.
Compd. EV71 (SZ-98) CVB3 CVB6
TC50 IC50 SI TC50 IC50 SI TC50 IC50 SI
mM mM mM mM mM mM
4a 280.12 431.13 – 193.83 13.65 14.20 193.83 31.13 6.23
4b 29.23 16.90 1.73 12.49 1.42 8.80 12.49 2.54 4.92
4c 97.88 427.24 – 47.06 49.08 – 47.06 49.08 –
4d 27.64 43.05 – 27.64 43.05 – 27.64 3.05 9.06
7a 39.65 49.20 – 48.04 7.15 6.72 48.04 3.06 15.70
7b 54.75 431.62 – 95.11 18.29 5.20 94.11 10.55 9.02
7c 112.06 425.88 – 77.69 48.63 – 77.69 3.77 20.60
7d 107.34 8.27 12.98 74.70 6.44 11.60 74.70 48.29 –
7e 46.05 411.99 – 46.05 411.99 – 46.05 3.05 15.10
7f 14.79 43.40 – 10.23 0.62 16.50 10.23 0.87 11.76
7g 46.22 428.62 – 55.05 20.39 2.70 45.68 2.91 15.70
7h 102.39 470.91 – 146.75 470.99 – 146.75 23.67 6.20
7i 133.15 39.63 3.36 191.80 30.87 6.21 190.80 39.75 4.80
8a 12.51 43.22 – 12.51 43.22 – 12.51 43.22 –
8b 174.41 100.86 1.73 389.79 78.36 4.97 389.79 18.13 21.50
8c 35.07 49.08 – 35.07 49.08 – 35.07 9.08 3.90
9a 261.90 487.48 – 261.90 29.10 9.00 262.19 15.70 16.70
9b 23.75 5.48 4.33 20.83 43.03 – 20.83 43.03 –
9c 61.60 48.81 – 61.60 2.92 21.10 61.61 3.78 16.30
9d 11.66 41.00 – 11.66 41.00 – 11.66 41.00 –
9e 15.07 48.69 – 11.25 2.25 5.00 11.23 2.88 3.90
9f 35.67 45.71 – 35.67 45.71 – 35.67 45.71 –
9g 111.10 453.36 – 111.10 453.41 – 111.10 453.41 –
9h 198.84 451.43 – 198.84 451.43 – 198.84 451.43 –
Pirodavir 15.39 0.32 48.09 ND ND ND ND ND ND
RBV ND ND ND 8205.90 2120.40 3.87 8205.90 911.77 9.00
Note: ND means not detected.
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with IC50 values of 13.65 and 31.13 mM, respectively. When
the 40-position of the ﬂavonoid system was functionalized with
a methoxy group, as in compound 4b, the inhibitory activity
was more potent against CVB3 and CVB6, with IC50 values of
1.42 and 2.54 mM being recorded, respectively. Compound 4c
showed no activity against CVB3 and CVB6, whereas com-
pound 4d only presented clear inhibitory activity against
CVB6, indicating that the presence of an electron donating
group on the phenyl ring favored the antiviral activity.
Of the thioﬂavone analogues tested in the current study,
compound 7f showed the highest level of inhibitory activity
against both CVB3 and CVB6 with an IC50 value of 0.62 and
0.87 mM, respectively. Compound 7d, which contained an
electron donating group (methoxy) at the 40-position of the
phenyl ring also showed a high level of inhibitory activity
against CVB3, with an IC50 value of 6.44 mM and a selectivity
index (SI) of 11.60. In contrast, compounds 7c and 7h, which
contained electron withdrawing groups (ﬂuorine and nitro) at
the 40-position of the phenyl ring, showed no activity against
CVB3. Taken together, these results indicate that the presence
of an electron donating group at the 40-position of the
thioﬂavone ring system is beneﬁcial to the antiviral activity.
Compound 7b also showed moderate inhibitory activity
against CVB3 with an IC50 value was 18.29 mM. Compounds
7a, 7c, 7e and 7g all showed strong levels of inhibitory activity
against CVB6 at very low concentrations (IC50¼2.91–
3.77 mM). Furthermore, the SI values in these compounds
(415) were much higher than that of the reference drug.
Compound 7c gave the highest SI value of all of the
compounds tested against CVB6 at up to 20.6. The ether
cleavage compounds 8a–c showed weak to no activity against
CVB3, whereas compound 8c showed a moderate level of
activity against CVB6, with an IC50 value of 9.08 mM.
As shown in Table 1 and Fig. 2, the isoﬂavones 9c and 9e
showed high levels of inhibitory activity against both the
CVB3 and CVB6 strains, with IC50 values of 2.25–3.78 mM.
Furthermore, compound 9c showed high SI values of 21.1 and
16.3 against CVB3 and CVB6, respectively. Compound 9a
also exhibited inhibitory activity against CVB3 and CVB6.
Unfortunately, none of the remaining isoﬂavones tested
showed any activity against CVB3 or CVB6.
In summary, all of the synthesized and purchased com-
pounds were assayed to determine their in vitro antiviral
activity against EV71, CVB3 and CVB6. The majority of the
compounds exhibited promising antiviral activity, especiallyFigure 2 Structures of the commercial compounds 9a–h.compound 4b, which showed activity against all of the viruses
tested, indicating that it possessed broad-spectrum antiviral
activity. In addition, compounds 7a, 7f, 9c and 9e showed
strong inhibitory activity against both the CVB3 and CVB6
strains. We believe that the active compounds are worthy of
further evaluation as novel lead compounds for the develop-
ment of broad spectrum antiviral agents.3. Experimental procedures
3.1. Chemistry
All solvents and reagents were of chemical or analytical grade.
The progress of the reactions was monitored by TLC using
solvent systems of different polarities. 1H NMR spectra were
recorded in CDCl3 or DMSO-d6 on a Varian Inova 400/
500 MHz spectrometer (Varian, San Francisco, CA, USA).
Chemical shift was reported in parts per million relative to a
tetramethylsilane internal standard. Melting points were
determined with an X-4 microscope melting point apparatus
and were uncorrected. All mass spectra (MS, HR-MS) were
recorded on a LTQ-Orbitrap linear ion trap high-resolution
mass spectrometer (ThermoFisher Scientiﬁc, San Jose,
CA, USA).
3.1.1. General procedure for the synthesis of compounds 4a–d
2-Hydroxy acetophenone 1 (1.36 g, 0.01 mol) and benzaldehyde
2 (1.06 g, 0.01 mol) were added to a solution of KOH (1.12 g,
0.02 mol) in methanol (50 mL) at 0–5 1C. The reaction mixture
was stirred over night at room temperature and then poured
over crushed ice and acidiﬁed to pH 6 with 2 M HCl. The
resulting yellow solid was ﬁltered and the ﬁlter-cake washed with
water to give the crude product that could either be recrystal-
lized from ethanol to afford pure 2-hydroxychalcones 3a or used
directly in the next reaction without further puriﬁcation.
30% H2O2 (10 mL) was added to a well-stirred solution of
3a (1.57 g, 0.007 mol) and 20% (w/w) aqueous KOH (10 mL)
in MeOH (20 mL) at 5–10 1C in a drop-wise manner over 1 h.
The resulting reaction mixture was stirred for 10 h and then
poured on crushed ice and neutralized with 2 M HCl. EtOAc
(50 mL) was added and the organic layer was washed
successively with water, a saturated solution of NaHCO3,
water and brine and then dried over anhydrous MgSO4. The
solvent was removed in vacuo and the residue was puriﬁed by
column chromatography on silica gel (AcOEt/n-hexane¼1/3
to 1/1) to give the title compound 4a as a white solid.
3-Hydroxy-2-phenyl-4H-chromen-4-one (4a): yield 55%,
mp. 172–173 1C; 1H NMR (500 MHz, DMSO-d6) d: 7.34
(1H, m), 7.40 (4H, m), 7.80 (2H, m), 8.23 (1H, m), 9.61 (1H,
s); MS (ESIþ) m/z: 239.1 [MþH]þ; HR-MS (ESIþ) m/z:
239.0714 [MþH]þ, Calcd. for C15H11O3 239.0708.
3-Hydroxy-2-(3-methoxyphenyl)-4H-chromen-4-one (4b):
yield 65%, mp. 140–142 1C; 1H NMR (400 MHz, DMSO-d6)
d: 3.83 (3H, s), 7.08 (1H, m, J¼2.8 Hz, J¼8.4 Hz), 7.46 (2H,
m), 7.80 (4H, m), 8.12 (1H, dd, J¼1.2 Hz, J¼8.4 Hz), 9.63
(1H, s); MS (ESIþ) m/z: 269.1 [MþH]þ; HR-MS (ESIþ) m/z:
269.0822 [MþH]þ, Calcd. for C16H13O4 269.0814.
2-(4-Chlorophenyl)-3-hydroxy-4H-chromen-4-one (4c): yield
62%, mp. 189–191 1C; 1H NMR (500 MHz, DMSO-d6) d: 7.47
(1H, t, J¼7.0 Hz), 7.64 (2H, d, J¼8.5 Hz), 7.79 (2H, m), 8.10
(1H, d, J¼7.0 Hz), 8.25 (2H, d, J¼8.5 Hz), 9.84 (1H, s); MS
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[MþH]þ, Calcd. for C15H10Cl 273.0318.
3-Hydroxy-2-p-tolyl-4H-chromen-4-one (4d): yield 59%,
mp. 112–114 1C; 1H NMR (400 MHz, DMSO-d6) d: 2.38
(3H, s), 7.37 (2H, d, J¼8.0 Hz), 7.46 (1H, m), 8.12 (3H, m),
9.52 (1H, s); MS (ESIþ) m/z: 253.1 [MþH]þ; HR-MS (ESIþ)
m/z: 253.0869 [MþH]þ, Calcd. for C16H13O3 253.0865.3.1.2. General procedure for the synthesis of compounds 7a–i
4-Methoxybenzenethiol 5 (1.40 g, 10 mmol) was added to
polyphosphoric acid (12 mL) preheated to 90 1C under
mechanical stirring. At this temperature, ethyl benzoylacetate
6a (1.92 g, 10 mmol) was added slowly in a drop-wise manner
to the mixture, and stirring was continued for 3 h after the
addition. The cooled mixture was vigorously stirred with ice/
water and extracted with ethyl acetate. The combined organic
layers were washed with brine, dried over magnesium sulfate,
and evaporated in vacuo. The crude product was puriﬁed by
silica gel chromatography (AcOEt/n-hexane¼1/3 to 1/2) to
give the 7a as colorless crystals.
6-Methoxy-2-phenyl-4H-thiochromen-4-one (7a): yield 54%,
mp. 159–160 1C; 1H NMR (400 MHz, CDCl3) d: 3.96 (3H, s),
7.30 (1H, dd, J¼2.8 Hz, J¼8.8 Hz), 7.42 (s, 1H), 7.52 (m, 3H),
7.63 (1H, d, J¼8. 8 Hz), 7.72 (2H, m), 8.02 (1H, d, J¼2.8 Hz);
MS (ESIþ) m/z: 269.1 [MþH]þ, 291.0 [MþNa]þ; HR-MS
(ESIþ) m/z: 269.0638 [MþH]þ, Calcd. for C16H13O2S 269.0631.
6-Methoxy-2-propyl-4H-thiochromen-4-one (7b): yield
48%, mp. 59–60 1C; 1H NMR (400 MHz, CDCl3) d: 1.01 (t,
3H, J¼7.2 Hz), 1.78 (2H, m), 2.67 (2H, t, J¼7.6 Hz), 3.92
(3H, s), 6.90 (1H, s), 7.21 (1H, dd, J¼2.8 Hz, J¼8.8 Hz), 7.48
(1H, d, J¼8.8 Hz), 7.96 (1H, d, J¼2.8 Hz); MS (ESIþ) m/z:
235.2 [MþH]þ, 257.1 [MþNa]þ; HR-MS (ESIþ) m/z:
235.0793 [MþH]þ, Calcd. for C13H15O2S 235.0787.
2-(4-Fluorophenyl)-6-methoxy-4H-thiochromen-4-one (7c):
yield 45%, mp. 139–141 1C; 1H NMR (400 MHz, CDCl3) d:
3.96 (3H, s), 7.20 (2H, m), 7.29 (1H, m), 7.27 (1H, s), 7.59 (1H,
d, J¼8.8 Hz), 7.70 (2H, m), 8.00 (1H, d, J¼2.8 Hz); MS
(ESIþ) m/z: 287.2 [MþH]þ, 309.1 [MþNa]þ; HR-MS (ESIþ)
m/z: 287.0544 [MþH]þ, Calcd. for C16H12O2FS 287.0537.
6-Methoxy-2-(4-methoxyphenyl)-4H-thiochromen-4-one
(7d): yield 57%, mp. 162–164 1C; 1H NMR (400 MHz, CDCl3)
d: 3.88 (3H, s), 3.96 (3H, s), 7.02 (2H, m), 7.28 (1H, dd,
J¼8.8 Hz, J¼2.8 Hz), 7.41 (1H, s), 7.60 (1H, d, J¼8.8 Hz),
7.69 (2H, m), 8.00 (1H, d, J¼2.8 Hz); MS (ESIþ) m/z: 299.1
[MþH]þ. HR-MS (ESIþ) m/z: 299.0745 [MþH]þ, Calcd. for
C17H15O3S 299.0736.
6-Methoxy-2-methyl-4H-thiochromen-4-one (7e): yield 60%,
mp. 100–102 1C; 1H NMR (400 MHz, DMSO-d6) d: 2.49 (3H, s),
3.93 (3H, s), 6.92 (1H, s), 7.23 (1H, dd, J¼3.2 Hz, J¼8.8 Hz),
7.48 (1H, d, J¼8.8 Hz), 7.96 (1H, d, J¼3.2 Hz); MS (ESIþ) m/z:
207.2 [MþH]þ, 229.2 [MþNa]þ; HR-MS (ESIþ) m/z: 207.0479
[MþH]þ, Calcd. for C11H11O2S 207.0474.
2-(Chloromethyl)-6-methoxy-4H-thiochromen-4-one (7f):
yield 40%, mp. 129–132 1C; 1H NMR (400 MHz, DMSO-d6)
d: 3.88 (3H, s), 4.95 (2H, s), 7.12 (1H, s), 7.41 (1H, dd,
J¼2.8 Hz, J¼8.8 Hz), 7.76 (1H, d, J¼2.8 Hz), 7.87 (1H, d,
J¼8.8 Hz); MS (ESIþ) m/z: 241.2 [MþH]þ, 263.2 [MþNa]þ;
HR-MS (ESIþ) m/z: 241.0082 [MþH]þ, Calcd. for
C11H10ClO2S 241.0090.
6-Methoxy-2-methyl-3-phenyl-4H-thiochromen-4-one (7g):
yield 58%, mp. 107–109 1C; 1H NMR (400 MHz, DMSO-d6)d: 2.21 (3H, s), 3.86 (3H, s), 7.18 (2H, d, J¼6.8 Hz,), 7.40 (3H,
m), 7.38 (1H, dd, J¼2.8 Hz, J¼8.8 Hz), 7.76 (1H, d, J¼2.8
Hz), 7.79 (1H, d, J¼8.8 Hz); MS (ESIþ) m/z: 283.5 [MþH]þ,
305.3 [MþNa]þ. HR-MS (ESIþ) m/z: 283.0795 [MþH]þ,
Calcd. for C17H15O2S 283.0787.
6-Methoxy-2-(4-nitrophenyl)-4H-thiochromen-4-one (7h):
yield 45%, mp. 186–188 1C; 1H NMR (400 MHz, DMSO-d6)
d: 3.91 (3H, s), 7.39 (1H, s), 7.46 (1H, dd, J¼2.8 Hz, J¼8.8
Hz), 7.83 (1H, d, J¼2.8 Hz), 7.95 (1H, d, J¼8.8 Hz), 8.04
(2H, d, J¼8.8 Hz), 8.44 (2H, d, J¼8.8 Hz); MS (ESIþ) m/z:
314.2 [MþH]þ; HR-MS (ESIþ) m/z: 314.0491 [MþH]þ, Calcd.
for C16H12O4NS 314.0482.
3-Chloro-6-methoxy-2-methyl-4H-thiochromen-4-one (7i):
yield: 40%, mp. 90–93 1C; 1H NMR (400 MHz, DMSO-d6)
d: 2.47 (3H, s), 3.86 (3H, s), 7.35 (1H, dd, J¼2.8 Hz, J¼8.8
Hz), 7.76 (1H, d, J¼2.8 Hz), 7.77 (1H, d, J¼8.8 Hz); HR-
MS(ESIþ) m/z: 241.0091 [MþH]þ, Calcd. for C11H10O2ClS,
241.0085.
3.1.3. General procedure for the synthesis of compounds 8a–c
Compound 7a (268 mg, 1.0 mmol) was dissolved in dry dichlor-
omethane (30 mL) and treated with a 1 M solution of boron
tribromide (4 mL, 4 mmol) in DCM with ice-cooling. The
mixture was stirred for 1 h at room temperature and then poured
onto ice/water. The organic layer was separated, washed cau-
tiously with aqueous sodium bicarbonate solution, dried over
magnesium sulfate, and concentrated in vacuo. The residue was
puriﬁed by chromatography on silica gel (AcOEt/n-hexane ¼1/3
to 1/2) to give the desired product as colorless crystals.
6-Hydroxy-2-phenyl-4H-thiochromen-4-one (8a): yield
45%, mp.4270 1C; 1H NMR (400 MHz, DMSO-d6) d: 7.71
(1H, s), 7.25 (1H, dd, J¼2.8 Hz, J¼8.8 Hz), 7.56 (3H, m),
7.72 (1H, d, J¼2.8 Hz), 7.79 (3H, m), 10.27 (1H, s); MS
(ESIþ) m/z: 255.1 [MþH]þ, 257.1 [MþNa]þ; HR-MS (ESIþ)
m/z: 255.0481 [MþH]þ, Calcd. for C15H11O2S 255.0474.
6-Hydroxy-2-propyl-4H-thiochromen-4-one (8b): yield
64%, mp. 147–149 1C; 1H NMR (400 MHz, DMSO-d6) d:
0.93 (3H, t, J¼7.2 Hz), 1.68 (2H, m), 2.68 (2H,t, J¼7.2 Hz),
6.79 (1H, s), 7.18 (1H, dd, J¼2.8 Hz, J¼8.8 Hz), 7.67 (2H,
m), 10.15 (1H, s); MS (ESIþ) m/z: 221.13 [MþH]þ, 243.1
[MþNa]þ; HR-MS (ESIþ) m/z: 221.0635 [MþH]þ, Calcd. for
C13H13O2S 221.0631.
2-(4-Fluorophenyl)-6-hydroxy-4H-thiochromen-4-one (8c):
yield 58%, mp. 157–159 1C; 1H NMR (400 MHz, DMSO-d6)
d: 7.16 (1H, s), 7.25 (1H, dd, J¼2.8 Hz, J¼8.4 Hz), 7.40 (2H,
m), 7.72 (1H, d, J¼2.8 Hz), 7.87 (2H, m), 10.27 (1H, s); MS
(ESIþ) m/z: 273.1 [MþH]þ, 295.0 [MþNa]þ; HR-MS (ESIþ)
m/z: 273.0388 [MþH]þ, Calcd. for C15H10O2SF 273.0380.
3.2. Anti EV71, coxsackie B3 and coxsackie B6 activity assay
The African green monkey kidney cells (Vero), coxsackie viruses
B3 (Nancy strain), coxsackie viruses B6 (Schmitt strain) were all
acquired from the Institute of Virology at the Chinese Academy
of Preventive Medicine. EV71 (SZ-98) was acquired from
Institute of Pathogen Biology, Chinese Academy of Medical
Sciences & Peking Union Medical College.
Conﬂuent VERO cells were grown in 96-well microplates
and infected with a 100 median tissue culture infective dose
(100TCID50) of the test strains. After an adsorption period of
1 or 2 h at 37 1C (1 h for EV71 adsorption, and 2 h for
Dajun Zhang et al.580coxsackie B3 and B6 adsorption), the monolayers were washed
with phosphate-buffered saline and incubated at 37 1C in the
maintenance medium in the absence (control) or presence of
different concentrations of the test compounds. The viral CPE
was observed when the viral control group reached 4, and the
antiviral activities (IC50) of the compounds were determined
using Reed and Muench analyses. The SI value was calculated
form TC50/IC50.
3.3. Cytotoxicity assay
The cytotoxicities of the compounds toward VERO cells were
monitored by CPE. VERO cells (2.5 104/well) were plated
into a 96-well plate, using pirodavir and ribavirin as positive
controls. Following a 24 h hold period the monolayer cells
were incubated in the presence of various concentrations of
the test compounds. Following 48 h of culture at 37 1C under
an atmosphere of 5% CO2 in an incubator, the cells were
monitored by CPE. The median toxic concentration was
calculated using Reed and Muench analyses.
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